- Home
- MTNB vs SNGX Comparison
MTNB vs SNGX Comparison
Compare MTNB & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTNB
- SNGX
- Stock Information
- Founded
- MTNB 2013
- SNGX 1987
- Country
- MTNB United States
- SNGX United States
- Employees
- MTNB N/A
- SNGX N/A
- Industry
- MTNB Biotechnology: Pharmaceutical Preparations
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- MTNB Health Care
- SNGX Health Care
- Exchange
- MTNB Nasdaq
- SNGX Nasdaq
- Market Cap
- MTNB 10.8M
- SNGX 10.1M
- IPO Year
- MTNB N/A
- SNGX 1987
- Fundamental
- Price
- MTNB $1.88
- SNGX $1.62
- Analyst Decision
- MTNB Hold
- SNGX Strong Buy
- Analyst Count
- MTNB 1
- SNGX 1
- Target Price
- MTNB N/A
- SNGX $6.00
- AVG Volume (30 Days)
- MTNB 57.2K
- SNGX 2.5M
- Earning Date
- MTNB 11-12-2025
- SNGX 11-07-2025
- Dividend Yield
- MTNB N/A
- SNGX N/A
- EPS Growth
- MTNB N/A
- SNGX N/A
- EPS
- MTNB N/A
- SNGX N/A
- Revenue
- MTNB N/A
- SNGX N/A
- Revenue This Year
- MTNB N/A
- SNGX N/A
- Revenue Next Year
- MTNB N/A
- SNGX N/A
- P/E Ratio
- MTNB N/A
- SNGX N/A
- Revenue Growth
- MTNB N/A
- SNGX N/A
- 52 Week Low
- MTNB $0.47
- SNGX $1.09
- 52 Week High
- MTNB $4.25
- SNGX $6.23
- Technical
- Relative Strength Index (RSI)
- MTNB 53.90
- SNGX 39.93
- Support Level
- MTNB $1.83
- SNGX $1.11
- Resistance Level
- MTNB $1.97
- SNGX $1.48
- Average True Range (ATR)
- MTNB 0.13
- SNGX 0.18
- MACD
- MTNB -0.01
- SNGX -0.04
- Stochastic Oscillator
- MTNB 46.94
- SNGX 29.71
About MTNB Matinas Biopharma Holdings Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).